APOE and Alzheimer disease: To address the above important knowledge gaps, using data from the UK Biobank Pharma Proteomics Project (UKB‐PPP), a study that involved large‐scale measurements of approximately 3000 proteins in 50,000 participants, we aimed to develop and validate a multi‐protein risk score for assessing the risk of AD, and compare its predictive performance with the latest validated clinical risk model (CogDrisk‐AD) and APOE genotypes.